[Molecular targeting therapy for bladder cancer]

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Molecular-targeted drugs offer a precise approach to cancer therapy by targeting specific molecules involved in cancer development.
• These agents aim to inhibit cancer growth, invasion, and metastasis while minimizing damage to healthy tissues.
• Key molecular targets include oncogene products, growth factors, signaling molecules, and factors influencing drug resistance, apoptosis, and angiogenesis.

Purpose of the Study:

• To review the current landscape of molecular-targeted drugs under consideration for bladder cancer.
• To highlight the specific molecular targets relevant to bladder cancer therapy.

Main Methods:

• Literature review of molecular-targeted drugs and their application in bladder cancer.
• Analysis of molecular targets implicated in bladder cancer progression and treatment.

Main Results:

• Identification of various molecular targets crucial for bladder cancer, such as growth factor receptors and cell cycle regulators.
• Overview of emerging molecular-targeted drugs showing potential in preclinical and clinical studies for bladder cancer.

Conclusions:

• Molecular-targeted therapy represents a promising strategy for advancing bladder cancer treatment.
• Further research and clinical trials are essential to fully realize the potential of these targeted agents in improving patient outcomes.